Vistagen Therapeutics Inc (NASDAQ:VTGN) Director Jon S. Saxe purchased 12,080 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was bought at an average cost of $1.26 per share, with a total value of $15,220.80. Following the acquisition, the director now owns 3,251 shares in the company, valued at approximately $4,096.26. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NASDAQ VTGN traded down $0.01 on Friday, hitting $1.27. The company had a trading volume of 495,452 shares, compared to its average volume of 272,780. The firm has a market cap of $54.55 million, a PE ratio of -1.14 and a beta of -0.34. Vistagen Therapeutics Inc has a 12-month low of $0.81 and a 12-month high of $2.44.

Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Tuesday, February 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). As a group, research analysts predict that Vistagen Therapeutics Inc will post -0.9 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its holdings in Vistagen Therapeutics by 13.0% in the 4th quarter. Geode Capital Management LLC now owns 154,457 shares of the company’s stock worth $231,000 after acquiring an additional 17,721 shares in the last quarter. Millennium Management LLC acquired a new stake in Vistagen Therapeutics during the 4th quarter worth $28,000. Northern Trust Corp boosted its stake in Vistagen Therapeutics by 168.6% during the 4th quarter. Northern Trust Corp now owns 69,642 shares of the company’s stock worth $104,000 after purchasing an additional 43,714 shares during the last quarter. D.A. Davidson & CO. boosted its stake in Vistagen Therapeutics by 22.9% during the 4th quarter. D.A. Davidson & CO. now owns 94,000 shares of the company’s stock worth $141,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Vanguard Group Inc boosted its stake in Vistagen Therapeutics by 42.7% during the 3rd quarter. Vanguard Group Inc now owns 257,465 shares of the company’s stock worth $373,000 after purchasing an additional 77,090 shares during the last quarter. 9.97% of the stock is owned by institutional investors.

Several equities research analysts recently commented on the stock. Maxim Group reissued a “buy” rating and issued a $6.00 price target on shares of Vistagen Therapeutics in a report on Wednesday, March 6th. ValuEngine lowered shares of Vistagen Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $8.30.

COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Read More: What is a Candlestick Chart?

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with's FREE daily email newsletter.